This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on Web of Science (1)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

A Double-Blind Study of 25 Cases

CAPT ROBERT G. NORFLEET, MC; CAPT HOWARD F. RICKENBACH, JR., MC

Arch Intern Med. 1964;113(3):412-414.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Since the etiology of infectious mononucleosis is unknown, treatment remains symptomatic. Agents such as convalescent serum,¹ corticotropin,² cortisone derivatives,^3,4 and -globulin⁵ have been used. Their efficacy has been equivocal and difficult to evaluate due to the lack of suitable controls in most instances and due to the variability of the severity of the disease. In 1960, Gothberg ⁶ reported dramatic improvement of the symptoms and fever in four patients with infectious mononucleosis when treated with chloroquine phosphate. The purpose of this study is evaluation of chloroquine phosphate in the treatment of infectious mononucleosis utilizing a double-blind technique.

Materials and Methods

All patients admitted to the USAF Hospital, Wright-Patterson Air Force Base, from October, 1961, to September, 1962, with suspected infectious mononucleosis were examined by us and were included in this study. Chloroquine phosphate (Aralen) 250 mg or an identical placebo tablet * was administered from a numbered . . . [Full Text PDF of this Article]

Author Affiliations
From the Internal Medicine Service Section, USAF Hospital, Wright-Patterson Air Force Base, Ohio.

Footnotes
Received for publication Sept 25, 1963; accepted Oct 19.

The views expressed herein are those of the authors and do not necessarily reflect the views of the United States Air Force or The Department of Defense.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?